Welcome to our dedicated page for Cardiac Biotech Solutions news (Ticker: CBSC), a resource for investors and traders seeking the latest updates and insights on Cardiac Biotech Solutions stock.
Cardiac Biotech Solutions, Inc. (CBSC) is a medical technology company that regularly issues news updates about its non-invasive ambulatory cardiac monitoring products, regulatory milestones, and international distribution activities. Its disclosures focus on the MyCardia AT and CardioHolter AT cardiac event monitoring platforms, which combine wearable devices with AWS Cloud-based connectivity and mobile applications.
News coverage for CBSC often highlights regulatory approvals and submissions, such as FDA clearance for MyCardia AT in the United States and a Medical Device License from Health Canada for the CardioHolter AT in Canada. The company also reports on progress toward regulatory clearance in China through collaborations with licensed NMPA medical device manufacturers and hospital-based clinical field testing.
Investors and healthcare observers following CBSC’s news can expect announcements about distribution agreements and purchase orders in key markets. Recent releases have described exclusive distribution arrangements with partners in Canada, Central America, and South America, as well as initial purchase orders for thousands of devices that support the company’s combined device sales and recurring rental revenue model.
Additional CBSC news items address corporate developments, including the company’s name change from CB Scientific, Inc. to Cardiac Biotech Solutions, Inc., voluntary delisting from the OTCQB Venture Market while continuing to trade on the OTC Pink Open Market, and updates on financing efforts and technology initiatives. For readers interested in how remote cardiac monitoring technologies are being deployed across multiple regions and regulatory environments, the CBSC news feed provides ongoing insight into the company’s product launches, partnerships, and strategic steps in the ambulatory cardiac monitoring space.
CB Scientific (CBSC) is advancing its strategic goals in the Ambulatory Remote Cardiac Monitoring market since June 2020, despite challenges posed by the COVID-19 pandemic. The company highlights key advancements, including the launch of My-Cardia ECG services in Thailand and acquisition plans for DATRIX LLC. Additionally, my-Cam device registrations in Malaysia and Singapore are set for March and April 2021, respectively. Clinical trials are ongoing with over 250,000 successful transmissions. CBSC aims for substantial growth thanks to market expansions and strategic collaborations.
CB Scientific Inc. (CBSC) has entered a collaborative partnership with Shenzhen Semacare Medical Technology to advance remote cardiac monitoring solutions. This partnership aims to leverage Semacare's MetaCor monitoring device and MetaAI technology, facilitating regulatory approvals for both companies' products in international markets. CBSC will assist Semacare in obtaining CE and FDA approvals while receiving support for its my-Cam device in China. The agreement also explores potential joint product development and future strategic business combinations.
CB Scientific (OTC: CBSC) has entered into an exclusive distribution agreement with Mango Wellness Co., Ltd. and My Cardia Thailand Co., Ltd. to launch its FDA and CE-cleared EKG products in Thailand, effective October 29, 2020.
The partnership aims to deliver advanced cardiac monitoring solutions to over 1,300 hospitals in Thailand, addressing the rising incidence of cardiovascular diseases. This move sets the stage for further expansions into Malaysia and Singapore, enhancing CBSC's footprint in the Asian market.